Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.
Actively Recruiting
Researchers are evaluating the performance of the Panuri test in detecting pancreatic ductal adenocarcinoma PDAC, the most common type of pancreatic cancer. This observational study focuses on adult patients who show symptoms suggesting pancreatic cancer or who are scheduled for procedures involving pancreatic cancer assessment. Panuri is a laboratory test designed to detect enzyme activity in urine samples related to PDAC, intended to support doctors in deciding if further imaging tests are needed. Participants will provide urine samples for the Panuri test during the study. The study includes two groups one with patients showing symptoms of pancreatic cancer and another with patients scheduled for pancreatic tissue assessment due to cancer suspicion. The test results will be kept blinded from both participants and physicians. Diagnosis confirmation will be done through review of electronic health records. Participants will be monitored from enrollment up to six months to assess how well the Panuri test detects PDAC. Data such as urine samples and medical records will be collected, but no treatment or intervention will be given as part of the study. The study aims to provide important information to help improve the diagnosis process for pancreatic cancer.